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Background and Aims. Functional gastrointestinal disorders (FGDs) are multifactorial disorders of the gut-brain interaction. This
study investigated the prevalence of Axis I and spectrum disorders in patients with FGD and established the link between FGDs and
psychopathological dimensions.Methods. A total of 135 consecutive patients with FGD were enrolled. The symptoms’ severity was
evaluated using questionnaires, while the psychiatric evaluation by clinical interviews established the presence/absence of mental
(Diagnostic and Statistical Manual—4th edition, Axis I Diagnosis) or spectrum disorders. Results. Of the 135 patients, 42
(32.3%) had functional dyspepsia, 52 (40.0%) had irritable bowel syndrome, 21 (16.2%) had functional bloating, and 20 (15.4%)
had functional constipation. At least one psychiatric disorder was present in 46.9% of the patients, while a suprathreshold panic
spectrum was present in 26.2%. Functional constipation was associated with depressive disorders (p < 0 05), while functional
dyspepsia was related to the current major depressive episode (p < 0 05). Obsessive-compulsive spectrum was correlated with
the presence of functional constipation and irritable bowel syndrome (p < 0 05). Conclusion. The high prevalence of
subthreshold psychiatric symptomatology in patients with FGD, which is likely to influence the expression of gastrointestinal
symptoms, suggested the usefulness of psychological evaluation in patients with FGDs.
1. Introduction
Functional gastrointestinal disorders (FGDs), better defined
as disorders of gut-brain interaction, are a combination of
various chronic or recurrent gastrointestinal symptoms with-
out a structural basis to explain their clinical features [1].
These include different disorders and involve the entire
digestive system. The symptoms of these disorders result
from a complex interplay among different and synergic
factors such as alterations of gut microbiota modulation
and mucosal immunity, visceral hypersensitivity, and central
nervous system dysregulation of the modulation of gut
signalling and motor function [1–4]. Given their relevance,
these factors should be encompassed in the relatively new
field of neurogastroenterology [5].
It is worth noting that these factors are the most
frequently reported conditions by the gastroenterologists
and constitute an important portion of the general practi-
tioner’s work; they cause significant absenteeism from work,
decrease the health-related quality of life, and increase the
medical costs [6, 7].
The cross-cultural aspects and psychological factors in
FGD are well recognized [8]. The psychological and environ-
mental factors together with the psychological distress affect
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both the clinical expression and symptom severity and thus
play a cocausative role in the onset and course of FGDs in
susceptible persons [2, 3, 9–13].
Anxiety, depression, and somatoform disorders are often
reported in patients with FGD, especially in those reporting
to gastroenterology clinics and/or referral centres. However,
this contrasts studies reporting patients with organic gastro-
intestinal problems who exhibit a lower prevalence of psychi-
atric disorders [14, 15].
Patients tend to consider their psychological problems as
a consequence of the same cause that produces FGDs. How-
ever, in almost half of the patients with a psychiatric disorder,
the psychopathological symptoms start before the gastroin-
testinal signs, while they begin at the same time in large por-
tion of the remaining patients [14, 16].
Although many studies demonstrated a strong associa-
tion between FGDs, psychological disturbances, and social
stress [9], relatively few studies directly reported a relation-
ship between FGDs and a well-defined psychiatric diagnosis.
Recently, Sahoo and Padhy [8] reviewed the cross-
cultural aspects and psychological factors in patients with
IBS. They essentially indicated that carefully collecting the
medical history and undertaking a holistic approach were
relevant for the management of patients with IBS. Moreover,
they outlined that a multidimensional approach, including
both a psychiatric and gastroenterological assessment, is an
essential part of an effective management of FGDs. In addi-
tion, on the basis of other multidisciplinary care models, a
sharp decrease in health care resources should be expected
because it could increase the efficacy and efficiency of
the disease management, reaching a more rapid diagnosis,
accelerating treatment planning, avoiding unnecessary
duplication of tests, decreasing the patients’ anxiety, and
shortening the waiting times for receiving a coordinated
plan of care [17].
Previously, the lack of reliable diagnostic criteria for
classifying FGDs and mental disorders represented the most
important methodological bias. In the last 20 years, the intro-
duction of the DSM system and the Rome criteria strongly
contributed to clarify better this intriguing matter.
Studies [14, 18–20] assessing the comorbidity of psychi-
atric symptoms and FGDs applied a traditional categorical
diagnosis according to the different systems of classification
of mental disorders (International Classification of Diseases
[ICD-9], ICD-10, DSM-III-revised, and DSM-IV). Although
these studies significantly contributed to the specification of
this relationship, the categorical view of mental illness risks
did not consider a large part of psychopathological signs
and symptoms under the diagnostic threshold that may
influence clinical management and prognosis of FGDs, such
as other medical and psychiatric disorders.
The concept of spectrum disorders [21] has been devel-
oped in order to identify the whole amount of psychopatho-
logical signs and symptoms characterizing a mental disorder
more efficiently. In addition to typical DSM core symptoms,
the spectrum comprises isolated or atypical symptoms, often
of low severity, as well as trait-behavioural features, which
tend to persist, waxing and waning, through the lifespan.
This use of prodromal, subthreshold, typical, atypical,
residual, and trait-like symptoms allows a dimensional eval-
uation of anxiety and mood phenomena and a better com-
prehension of the psychopathological continuum [22–24].
Therefore, several assessment instruments, including
structural interviews and self-report questionnaires, were
developed and tested in recent years [25].
Based on these observations, the aims of this study
were to investigate the prevalence of Axis I and spectrum
disorders in a population of patients with FGD and to
establish the possible links between some FGDs and some
psychopathological dimensions.
2. Patients and Methods
From 1 February 2013 to 31 July 2014, 135 consecutive
patients with FGD (34 men [25.2%], 101 women [74.8%];
mean age 43.22± 15.05 years; age range 18–70 years),
referred to the gastroenterology outpatient services of the
Gastrointestinal Unit of the University of Pisa, Italy, were
enrolled in this study.
The inclusion criteria were as follows: (1) patients
referred for functional gastrointestinal disorders at the
Gastroenterology Unit and (2) age range 18–70 years.
The following exclusion criteria were considered: (1)
severe organic diseases; (2) significant changes in serum
chemistry; (3) history of abdominal surgery (except appen-
dectomy); (4) lactose intolerance (demonstrated by lactose
breath test); (5) pregnancy; and (6) medication taken within
15 d prior to the study, which alters the autonomic response
(e.g., anticholinergic drugs or beta blockers), psychotropic
activity (e.g., tricyclic antidepressants, serotonin [5-HT]
reuptake inhibitors, or benzodiazepines), and/or that poten-
tially interfere with the gastrointestinal motility.
The study protocol was approved by the Ethical Com-
mittee of Pisa and was carried out in accordance with the
tenets of the Helsinki Declaration (6th Revision, Seoul, 2008).
Furthermore, written informed consent was obtained from
each participant.
2.1. Gastroenterological Evaluation. The patients were
grouped in accordance with their FGD: 42 (32.3%) were
diagnosed with functional dyspepsia (FD), 52 (40.0%)
with irritable bowel syndrome (IBS), 21 (16.2%) with
functional bloating (FB), and 20 (15.4%) with functional
constipation (FC).
The diagnosis of the different FGDs was performed in
accordance with the Rome III criteria [26, 27].
The severity of the symptoms was evaluated using
specific questionnaires including the IBS Symptom Severity
Score (IBS-SSS) to evaluate abdominal symptom severity
[28] and the Dyspepsia SSS [29]. Additionally, a “home-
made” bowel habits questionnaire using a scale ranging
from 0 (no symptoms) to 4 (symptoms present during
≥75% of bowel movements or days) [30] evaluated the
frequency of (1) painful defecation, (2) manual manoeu-
vres facilitating defecation, (3) hard faeces, (4) watery
faeces, (5) “fragmented” defecation, (6) sensation of anor-
ectal blockage, (7) urge to defecate, (8) incontinence for
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gas and/or faeces, (9) abdominal pain, and (10) abdomi-
nal bloating.
The degree of interference of the gastrointestinal symp-
toms with the global well-being was expressed by a visual
analogue scale (0–100mm), with 0 indicating absent and
100 indicating unbearable.
2.2. Psychiatric Evaluation. The psychiatric evaluations were
based on structured clinical interviews aimed to establish
essentially the presence or absence of (1) mental disorders
(DSM-IV Axis I diagnoses) and (2) spectrum disorder.
2.3. Instruments
2.3.1. Structured Clinical Interview for DSM-IV Patient
Edition (SCID IV). The Structured Clinical Interview for
DSM-IV Patient Edition (SCID IV) [31] was administered
to diagnose Axis I disorders using the DSM-IV categorical
criteria. SCID-IV is a hetero-evaluation instrument used to
assess psychiatric Axis I disorder into different nosographic
issues. The interview consists of a first part aimed to reveal
the demographic data, such as work and educational level,
as well as medical and pharmacological history. The second
part consists of different sessions: mood disorders, episodes
(session A), psychotic symptoms associated to mood disor-
ders (session B), psychotic disorders (session C), mood
disorders, course (session D), substance abuse disorders (ses-
sion E), anxiety disorders (session F), somatoform disorders
(session G), eating disorders (session H), and adjustment
disorders (session I).
2.3.2. Structured Clinical Interview for Panic-Agoraphobic
Spectrum—Self-Report Version (SCI PAS-sr). SCI-PAS [32]
is a clinical interview aimed to evaluate the presence or
absence of panic and agoraphobic spectrum symptomatol-
ogy. It consists of 114 items grouped into 8 domains: (1)
separation sensitivity; (2) panic-like symptoms (typical and
atypical); (3) stress sensitivity; (4) substance and medication
sensitivity; (5) anxious expectation; (6) agoraphobia; (7)
illness-related phobia; and (8) reassurance orientation. Every
item was coded as “true” (1) or “false” (0), and the diagnostic
threshold was 35.
2.3.3. Structured Clinical Interview for Mood Spectrum—Self-
Report Version (SCI MOODS-sr). SCI-MOOD [33] consists
of 140 dichotomous items aimed to evaluate the presence/
absence of mood spectrum signs and symptoms and grouped
into seven domains: (1) mood depressed; (2) mood manic;
(3) energy depressed; (4) energy manic; (5) cognition
depressed; (6) cognition manic; and (7) rhythmicity and
vegetative functions. The diagnostic threshold was 61.
2.3.4. Structured Clinical Interview for Anorexic-Bulimic
Spectrum—Self-Report Version (SCI ABS-sr). SCI ABS-sr
[34] is a clinical interview aimed to evaluate the presence or
absence of anorexic-bulimic spectrum symptomatology. It
consists of 134 items grouped into nine domains: (1) atti-
tudes and beliefs; (2) history of weight loss; (3) self-esteem
and satisfaction; (4) phobias; (5) avoidance and compulsive
behaviours; (6) weight maintenance; (7) eating disorders;
(8) associated features and consequences; and (9) impair-
ment and insight. The diagnostic threshold was 45 points
where the answer coded by yes was equal to 1.
2.3.5. Structured Clinical Interview for Obsessive-Compulsive
Spectrum—Self-Report Version (SCI OBS-sr). SCI OBS [35]
is a clinical interview aimed to evaluate the presence/absence
of obsessive-compulsive spectrum symptoms. The SCI-OBS
consists of 196 items grouped into seven domains: (1) child-
hood/adolescence experiences; (2) doubt; (3) hypercontrol;
(4) attitudes toward time; (5) perfectionism; (6) repetition
and automation; and (7) specific themes. Every item was
coded as present or absent, and the diagnostic threshold
was 59.
2.3.6. Structured Clinical Interview for Social Anxiety
Spectrum—Self-Report Version (SCI SHY-sr). SCI SHY [35]
is a clinical interview aimed to evaluate the presence/absence
of social anxiety spectrum symptoms and consists of 164
items grouped into four domains: (1) social phobic traits dur-
ing childhood and adolescence; (2) interpersonal sensitivity;
(3) behavioural inhibition and somatic symptoms; and (4)
specific anxiety and phobic features. The appendix explores
the use of psychoactive substances, which is a frequent com-
plication of the social anxiety disorder. The diagnostic
threshold was 59.
2.3.7. Statistical Analysis. All data were analysed using SPSS
(SPSS Inc., Chicago, IL, USA) and Stata 12 software (Stata
Statistical Software, College Station, TX, USA). All variables
are expressed as the mean± standard deviation. The numer-
ical comparison of the continuous data was performed using
the t-test for paired samples. Statistical significance was set at
a value of p < 0 05. The Chi-square test was used to evaluate
the categorical variables. Linear regression analysis between
two variables was performed using Pearson correlation.
We have performed the multinomial logistic regression
analysis to evaluate the associations between the global
well-being and spectrum disorders/Axis I diagnosis, the
well-being in IBS patients and spectrum disorders/Axis
I diagnosis, the well-being in FB patients and spectrum
disorders/Axis I diagnosis, the well-being in FD patients
and spectrum disorders/Axis I diagnosis, and the well-being
in FC patients and spectrum disorders/Axis I diagnosis.
In this analysis, the score≥ 40 was considered interfering
with well-being.
3. Results
Table 1 summarizes the functional gastrointestinal diagnosis
groups of patients with FDGs.
At least one diagnosis of the psychiatric Axis I disorder
was present in 46.9% of the patients. In particular, the gener-
alised anxiety disorder was diagnosed in 20.0% of the
patients, while panic disorders, including panic disorder,
panic without agoraphobia, and agoraphobia without panic
attack, were diagnosed in 27.7% of the patients. Mood
disorders were the most frequent and were diagnosed in
13.1% of the patients (Table 2).
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Regarding spectrum symptomatology, a suprathreshold
panic spectrum was present in 26.2% of the patients. Despite
the low prevalence of Axis I obsessive-compulsive disorder
(0.8%) and social phobia (1.5%), a high percentage of
the patients exhibited a positive obsessive (19.2%) and
social phobic (23.8%) spectrum. Of the entire popula-
tion, 39.2% had at least one spectrum symptomatology of
anxiety, while 43.1% had at least one spectrum symptomatol-
ogy of affective disorders.
A low prevalence (3.9%) of axis eating disorders
(anorexia, bulimia, and binge eating disorder) and a higher
(15.4%) suprathreshold spectrum symptomatology were also
observed.
Almost 13.1% of the patients had an Axis I mood disor-
der, while 20.8% had a positive mood spectrum (Table 2).
Table 3 summarizes the prevalence of psychiatric disor-
ders and spectrum symptomatology in the different FGDs.
Significant associations were observed between FGDs (in
particular FC) and Axis I diagnosis depressive disorders
(dysthymia and recurrent depression; p < 0 05), while
current major depressive episode was significantly related
to FD (p < 0 05).
When we considered the relationship between FGDs and
spectrum disorders, obsessive-compulsive spectrum was
significantly related to the presence of FC and IBS (p < 0 05).
Considering the severity of the gastrointestinal
symptoms and the degree of interference with the global
well-being of the patients, a social phobic spectrum showed
a significant correlation with IBS (p < 0 05). Indeed, in the
IBS group, the comorbidity with social phobia was related
to a lower level of well-being, particularly with symptoms
such as defecation urgency (p < 0 01) and abdominal pain
relieved by evacuation (p < 0 05). However, the presence of
spectrum disorders was positively related to the degree of
interference of the gastrointestinal symptoms with the sub-
jective global well-being. Thus, patients without an Axis I dis-
order or a suprathreshold spectrum had a significantly lower
level of interference with the global well-being (p < 0 05).
Moreover, the presence of obsessive, social phobic, and
eating positive spectrums significantly decreased the global
well-being score. Obsessive and eating spectrums were
directly related to the well-being impairment of the IBS
group, while the social phobic spectrum was related to the
impairment of the well-being of the FC and FB groups. A
positive mood spectrum was inversely related to the well-
being of the patients with IBS (Tables 4 and 5).
When we performed the multinomial logistic regres-
sion analysis, we found a significant association between
the global well-being and spectrum disorders (p = 0 01),
but we found no significant association between global
well-being and Axis I diagnosis (p = 0 26). When we
considered the different FGD groups, we found a signifi-
cant association between well-being in FC patients and
spectrum disorders (p = 0 03).
4. Discussion
The relationship between FGDs and psychiatric disorders
has been widely studied, but the results have been often con-
flicting, mainly because of the complexity of the question and
the methodological bias in many studies.
Our study fully reflected the disputes concerning the
intriguing question “irritable brain or irritable bowel.” The
results confirmed a high psychiatric comorbidity in FGDs,
particularly mood and anxiety disorders, in the sense of full
diagnosis (one-third of the sample met the criteria for the
Axis I mental disorder).
However, independently of the full-blown diagnosis, a
particular value of this study was the organisation for
analysis, using appropriate standardized instruments, of a
psychopathological dimension, often labelled as “vulnera-
bility psychological features” and observed initially by
gastroenterologists.
For the first time, this study analysed the subthreshold
psychiatric symptomatology in patients with different FGDs.
It also confirmed the previous observations about the high
prevalence of Axis I psychiatric disorders among patients
with FGD [3, 4, 9, 17, 30, 36], particularly anxiety and mood
disorders. Subthreshold psychiatric symptomatology is
formed by a variety of symptoms that do not conform to a
formal diagnosis of mental disorder according to standard
psychiatric classification, but it impacts significantly in
quality of life.
However, the presence of a psychiatric Axis I disorder
seemed to explain partly the complex relationship between
the brain and the gut, particularly the clinical expressivity
of the functional gastrointestinal disorders. In previous stud-
ies [3, 4, 36], investigating psychological disorders, we found
a high prevalence of psychological disorders, but we have also
found that many patients had elevated scores for psychopa-
thology, however without reaching a significant score for
diagnosis. This led us to investigate spectrum disorders in
patients with FGDs. The comorbidity between FGDs and
psychiatric disorders is not simply restricted to Axis I disor-
ders but it also widely extends to spectrum psychopathology,
such as subclinical, prodromal, or residual symptoms. Spec-
tra instruments permit the collection of underlying soft
psychopathological symptoms generally defined as neurotic
traits or stress-related symptoms. Spectrum diagnoses
showed a strong coherence with DSM-IV diagnoses and
provided additional clinical information. It is likely that this
assessment can be used in patients with nonpsychiatric disor-
ders to provide a more comprehensive picture of symptoms
and behavioural traits. Additionally, previous studies indi-
cated that the presence of spectrum symptomatology has a
clinical relevant significance as a predictor of outcome in
major depressive and bipolar disorders [37].
In this study, the use of the spectrum instruments has
enabled pointing out to the presence of a subthreshold
Table 1: Distribution (N, %) of different FGDs studied.
Functional gastrointestinal disorders (N 135) %
Functional constipation 20 15.4
Irritable bowel syndrome 52 40.0
Functional dyspepsia 42 32.3
Functional bloating 21 16.2
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psychopathology in 44.6% of the study sample, compared
with an almost overlapping percentage of diagnosis of Axis
I (46.9%). It is worth noting that a spectrum diagnosis was
also present in 27.5% of patients with no major psychiatric
disorder; therefore, these spectrum instruments are also very
useful in patients with nonpsychiatric disorders not affected
by Axis I disorders, for whom a traditional psychiatric
approach is not feasible.
The distribution of spectrum diagnoses in our sample
(PAS 26.2%, MOOD 20.8%, OBS 19.2%, SHY 23.8%, and
ABS 15.4%) demonstrated an affective continuum that char-
acterized the dimensional psychopathological profile of this
cohort with clinical nonpsychiatric disorders. Our data fur-
ther indicated a close relationship between FGDs and anxiety
spectrum symptomatology, such as that underlined by the
high prevalence of panic-agoraphobic, social phobic, and
obsessive-compulsive spectrums. In consideration of this,
the unspecific terms of “neuroticism” and “stress reaction”
often used to label patients with FGDs in the past may be
replaced by the term “anxious spectra.”
However, the low-grade inflammation associated with
the release of interleukin- (IL-) 1, IL-6, and tumour necrosis
factor- (TNF-) αmay activate the cerebral circuits via afferent
fibres [2]. Indeed, recent findings demonstrated that the gut
microbiota plays a pivotal role in stress-related psychiatric
disorders [38, 39] and that the sensitivity and gastrointestinal
motility are both regulated by the central and peripheral
nervous systems via the complex interplay between the brain
and gut [3, 4]. 5-HT plays a key role in the regulation of
visceral pain and in the secretion and initiation of the peri-
staltic reflex. However, altered levels of 5-HT are also
detected in many different psychiatric disorders such as anx-
iety, depression, obsessive-compulsive disorders, and phobia
[13, 17]. The 5-HT released in the gut from the enterochro-
maffin cells regulates the sensory, motor, and secretory func-
tions of the digestive system through interactions with
intrinsic and extrinsic nervous pathways. Intrinsic innerva-
tion to the gut is supplied by neurons of the ENS, including
the myenteric and submucosal plexus. Extrinsic innervation
is provided by the autonomic nervous system (both sympa-
thetic and parasympathetic) and is arranged to function in
a bidirectional manner [11, 40, 41]. Moreover, the 5-HT con-
centrations are regulated by its reuptake, which is operated
by the 5-HT transporter (SERT) expressed both in neurons
and intestinal epithelium [40–43].
Our data demonstrated that the presence of spectrum
diagnoses influences the clinical picture of FGDs, particularly
well-being, quality of life, and severity of the FGD symptoms.
Spectrum diagnoses tend to be related to a low well-being
referred by patients and to a higher severity of FGD symp-
toms. In fact, the presence of spectrum disorders, in particu-
lar in FC patients after multivariate analysis, was positively
associated with the degree of interference of the gastrointes-
tinal symptoms with the subjective global well-being. This
could indicate that psychic dimension may change the per-
ception of the symptoms.
This is possibly owing to the psychological disorders that
in turn lead to a chronic state of amplification of symptoms,
Table 2: Axis I and mood spectrum disorders in patients with functional gastrointestinal disorders.
Axis I diagnosis (N) % Spectrum Mean + SD Overthreshold
Anxiety disorders
Panic 24 18.5
SCI-PAS 25.99± 17.54 26.2 (34)Panic with agoraphobia 10 7.7
Agoraphobia without panic attack 2 1.5
Single phobia 4 3.1
Anxiety NAS 4 3.1
GAD 26 20.0
Social phobia 2 1.5 SCI-SHY 39.47± 31.07 23.8 (31)
OCD 1 0.8 SCI-OBS 39.64± 24.69 19.2 (25)
Somatoform disorders 2 1.5
Mood disorders
Past major depressive episode 13 10.0 SCI-MOODS 38.25± 24.45
20.8 (27)
Current major depressive episode 2 1.5
Recurrent depression 1 0.8 Dep 24.78± 17.24
Dysthymia 1 0.8 Man 13.48± 9.55
Somatization disorders 1 0.8
Eating disorders
Anorexia 1 0.8
SCI-ABS 20.53± 19.66 15.4 (20)Bulimia 4 3.1
BED 0 0.0
SCI-PAS: Structured Clinical Interview for Panic-Agoraphobic Spectrum—self-report version; SCI-SHY: Structured Clinical Interview for Social Anxiety
Spectrum; SCI-OBS: Structured Clinical Interview for Obsessive-Compulsive Spectrum; SCI-MOODS: Structured Clinical Interview for Mood Spectrum;
SCI-ABS: Structured Clinical Interview for Anorexic-Bulimic Spectrum.
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which originates either at the level of the CNS (hypervigi-
lance on physical perception) or at the visceral level (hyper-
sensitivity and hypermotility) [2].
Obsession, which is revealed by a positive obsessive-
compulsive spectrum, was correlated with FGDs such as FC
and IBS.
Interesting conclusions could be inferred from the
second part of the analysis regarding the spectrum psychopa-
thology, severity, and global well-being both in the whole
population and in the FGD groups. Higher gastroenterologi-
cal symptomatic scores with a social phobic spectrum were
detected in patients with IBS compared to the other FGD
groups. Social phobic psychopathological nucleus is based
on the overestimation of judgement and criticism from
others; it may be reflected by an increase of frequency and
severity of anxiety-mediated IBS symptoms. The correlation
with defecation urgency and pain relief after evacuation
Table 3: The prevalence of psychiatric disorders and spectrum symptomatology in the different FGDs.
FC % (N = 20) IBS % (N = 52) FD % (N = 42) FB % (N = 21)
At least 1 Axis I disorder 60.0 (12) 36.5 (19) 52.4 (22) 47.6 (10)
Panic 25.0 (5) 17.3 (9) 19.0 (8) 14.3 (3)
Panic with agoraphobia 15.0 (3) 3.8 (2) 9.5 (4) 4.8 (1)
Agoraphobia without panic 5.0 (1) 0.0 (0) 2.4 (1) 0.0 (0)
Single phobia 5.0 (1) 1.9 (1) 2.4 (1) 4.8 (1)
Anxiety NAS 5.0 (1) 1.9 (1) 0.0 (0) 9.5 (2)
GAD 20.0 (4) 17.3 (9) 26.2 (11) 14.3 (3)
Social phobia 5.0 (1) 1.9 (1) 0.0 (0) 0.0 (0)
OCD 0.0 (0) 0.0 (0) 2.4 (0) 0.0 (0)
Somatoform disorders 5.0 (1) 1.9 (1) 0.0 (0) 0.0 (0)
Past MDE 9.5 (2) 11.5 (6) 9.5 (4) 14.3 (3)
Current MDE 0.0 (0) 0.0 (0) 4.8 (2) 0.0 (0)
Recurrent depression 5.0 (1) 0.0 (0) 0.0 (0) 0.0 (0)
Dysthymia 5.0 (1) 0.0 (0) 0.0 (0) 0.0 (0)
Somatization disorders 0.0 (0) 0.0 (0) 2.4 (1) 0.0 (0)
Anorexia 0.0 (0) 0.0 (0) 2.4 (1) 0.0 (0)
Bulimia 5.0 (1) 1.9 (1) 2.4 (1) 4.8 (1)
BED 0.0 (0) 0.0 (0) 0.0 (0) 0.0 (0)
Spectrum symptomatology
Overthreshold SCI-OBS 35.0 (7) 9.6 (5) 19.0 (8) 23.8 (5)
Overthreshold SCI-SHY 25.0 (5) 21.2 (11) 31.0 (13) 14.3 (3)
Overthreshold SCI-PAS 30.0 (6) 21.2 (11) 28.6 (12) 23.8 (5)
At least 1 anxiety spectrum 50.0 (10) 32.7 (17) 42.9 (18) 33.3 (7)
Overthreshold SCI-ABS 25.0 (5) 9.6 (5) 16.7 (7) 14.3 (3)
Overthreshold SCI-MOODS 35.0 (7) 13.5 (7) 28.8 (10) 14.3 (3)
NAS: anxiety in autistic adults; GAD: generalized anxiety disorder; OCD: obsessive-compulsive disorder; MDE: mood disorder event; BED: bipolar disorder
event; SCI-PAS: Structured Clinical Interview for Panic-Agoraphobic Spectrum—self-report version; SCI-SHY: Structured Clinical Interview for Social
Anxiety Spectrum; SCI-OBS: Structured Clinical Interview for Obsessive-Compulsive Spectrum; SCI-MOODS: Structured Clinical Interview for
Mood Spectrum; SCI-ABS: Structured Clinical Interview for Anorexic-Bulimic Spectrum; FC: functional constipation; IBS: irritable bowel syndrome;
FD: functional dyspepsia; FB: functional bloating.
Table 4: Differences in FDGs between nonpsychiatric patients and
patients with the presence of Axis I and/or spectrum disorders.
Healthy
Axis I and/or
spectrum disorders
p
Global well-being 36.70 31.50 <0.05
IBS well-being 17.40 8.75 <0.01
FB well-being 5.70 4.19 ns
Dyspepsia well-being 10.90 12.06 ns
FC well-being 2.70 6.50 ns
Table 5: Difference between psychiatric disorders (DSM IV) versus
spectrum diagnosis stratified for well-being.
OBS SHY PAS MOODS ABS
Global well-being 26.80∗∗ 27.58∗∗ 32.79 29.07 27.25∗
IBS well-being 4.60∗∗ 10.32 8.24 6.30∗ 4.00∗∗
FB well-being 5.20 1.61∗ 2.50 4.63 2.50
FD well-being 11.20 13.70 13.82 11.85 13.50
FC well-being 5.80 1.94∗ 8.23 6.30 7.25
∗p < 0 05; ∗∗p < 0 01.
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seems to confirm this view. Indeed, the fear of decontrol in
the sphincter functions, which significantly increases the
defecation urgency, and the significant decrease in anxiety
levels after evacuation could be perceived by the patients
as a reduction in the pain and urgency.
The obsessive and social-phobic dimensions were shown
to be associated with “poor well-being”; thus, with a worse
quality of life, they were assessed as subjective satisfaction
and interference. However, PAS, MOOD, and ABS spectrum
diagnoses as well as Axis I of panic attack disorder (DAP)
generalised anxiety disorder and major depression; although
they were easier to collect in nonpsychiatric clinical practice,
they do not show equal predictive powers.
In particular, the well-being of patients with FGDs was
significantly impaired when the gastrointestinal disease was
associated with a positive obsessive and social phobic
spectrum.
Obsessive patients seemed to be highly limited in their
functioning by this reactivity and instability in evacuation,
thereby triggering an inhibitory behaviour and a reduction
in the quality of life. The association between low well-being
in patients with FB and social phobic spectrum underlines
the inhibited behaviour due to the fear of emitting intestinal
sounds in public.
Especially spectrum diagnosis interfered negatively with
the global well-being of the patients affected by FGDs,
regardless of the specific FGD type and the severity of the
gastrointestinal symptoms.
Subjective satisfaction, quality of life, and global well-
being are variables that may increase the level of sufferance
referred to a symptom, and they could also inspire the
patients to refer to a physician or a gastroenterologist.
5. Conclusions
In conclusion, the high presence of subthreshold psychiatric
symptomatology in patients with FGDs suggested the useful-
ness of psychological evaluations in these patients, in whom
probably a brief self-evaluation scale could be used in the
clinical gastroenterological practice, targeted to reveal
subclinical psychopathological features that are likely to
influence significantly the expression of the gastrointestinal
symptoms. The second step could be represented by the
evaluation of Axis I psychiatric disorders and the global level
of well-being. Further studies are needed to clarify further the
pathophysiology of psychological disorders often associated
with FGDs.
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